Megan McNicol, PharmD, BCACP

From 2015 to 2019, switching commercially insured patients between infliximab products yielded no patient out-of-pocket savings and resulted in no savings to insurance payers after 2019.

Infliximab biosimilars created price competition causing insurance claims costs for infliximab originator and infliximab biosimilars to decrease, generating significant savings to the health care system.